pyrazines has been researched along with Adrenocortical Carcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arosio, M; Catalano, R; Elli, FM; Giardino, E; Luconi, M; Mangili, F; Mannelli, M; Mantovani, G; Morelli, V; Peverelli, E; Serban, AL; Spada, A; Treppiedi, D | 1 |
| Colao, A; de Herder, WW; de Krijger, RR; De Martino, MC; Dogan, F; Feelders, RA; Hofland, LJ; Hofste Op Bruinink, D; Janssen, JAMJL; Pivonello, C; Pivonello, R; van Koetsveld, PM; Waaijers, AM | 1 |
| Baudin, E; Berruti, A; Chen, J; Choueiri, TK; Demeure, MJ; Fassnacht, M; Fleege, T; Gilbert, J; Haak, H; Hammer, GD; Hesseltine, E; Kroiss, M; Poondru, S; Quinn, DI; Ronchi, CL; Rorig, R; Stephens, AW; Terzolo, M; Worden, F | 1 |
| Kirschner, LS | 1 |
| Brandalise, SR; Cardinalli, I; de Castro, M; Fedatto, PF; Leal, LF; Marco Antonio, DS; Martinelli, CE; Mastellaro, MJ; Neder, L; Peixoto Lira, RC; Ramalho, L; Rauber Antonini, SR; Scrideli, CA; Seidinger, AL; Tone, LG; Tucci, S; Yunes, JA | 1 |
1 trial(s) available for pyrazines and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
Topics: Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Placebos; Protein Kinase Inhibitors; Pyrazines | 2015 |
4 other study(ies) available for pyrazines and Adrenocortical Carcinoma
| Article | Year |
|---|---|
The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
Topics: Actin Cytoskeleton; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Filamins; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin-Like Growth Factor II; Mitogens; Pyrazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Tumor Cells, Cultured | 2021 |
IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Female; Humans; Imidazoles; Insulin-Like Growth Factor I; Male; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Inhibition of IGF-1R in adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Female; Humans; Imidazoles; Male; Neoplasm Metastasis; Pyrazines | 2015 |
IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Androgens; Androstenedione; Apoptosis; Cell Line, Tumor; Child; Child, Preschool; Dehydroepiandrosterone Sulfate; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Infant; Insulin-Like Growth Factor II; Male; Neoplasm Recurrence, Local; Phosphoproteins; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Messenger; Testosterone | 2016 |